The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical development of an anti-CD30/anti-CD16A bispecific tetravalent TandAb antibody for the treatment of Hodgkin lymphoma.
Stefan Knackmuss
Employment or Leadership Position - Affimed Therapeutics
Uwe Reusch
Employment or Leadership Position - Affimed Therapeutics
Carmen Burkhardt
Employment or Leadership Position - Affimed Therapeutics
Ivica Fucek
Employment or Leadership Position - Affimed Therapeutics
Fabrice Le Gall
No relevant relationships to disclose
Hans-Gerd Pauels
Consultant or Advisory Role - Pauels Consulting
Melvyn Little
Employment or Leadership Position - Affimed Therapeutics
Consultant or Advisory Role - Affimed Therapeutics
Stock Ownership - Affimed Therapeutics
Eugene Zhukovsky
Employment or Leadership Position - Affimed Therapeutics
Stock Ownership - Affimed Therapeutics